<b>Gapping up<br/>In reaction to strong earnings/guidance</b>: CAMP +12.7%, ZHNE +11.1%, ANGI +9.1%, VASC +6.9%, BRCM +6.6%, OC +4.9%, YUM +3.3%, AN +3.2%, DLB +3.1%, INFN +2.9%, AMGN +2.5%, IBKR +2.5%, KO +2.5%, MCD +2.2%, ZIXI +1.9%, TRCB +1.7%, DWCH +1.5%, ABT +1.4%, NBR +1.3%, WAB +1.3%, BABY +1.2%, BABY +1.2%, UCFC +1.1%, YHOO +1.1%, INTU +1%, (reports TurboTax Online units grew 13% from prior year; now expects FY15 consumer tax rev growth of ~8%, above prior guidance of +5-7% ), BK +1%, STJ +0.7%<br/><br/><b>M&A news:</b> PKT +20.3% (to be acquired by Francisco Partners for ~$240 mln, or $11.50/share in cash; reports preliminary Q1 revenues that exceed consensus estimates)<br/><br/><b>Select biotech/pharma related names showing strength with many peers releasing data this morning: </b>ONCY +28.6%, ENZN +4.7%, AVEO +3.6%, AMGN +2.4%<br/><br/><b>Other news: </b>GBSN +39.3% (receives FDA clearance for Group B Strep molecular diagnostic test; plans to launch commercially in 2Q15), ONVO +19.5% (reported earnings, but also entered into a multi-year research collaboration agreement with Merck Sharp & Dohme Corp), ATOS +11.1% (secures in-network contract With Meridian Health Plan of Michigan), ASML +10.7% (reaches agreement for delivery of minimum of 15 EUV lithography systems), VICL +5.8% (announces a $4 million contract with the IPPOX Foundation to manufacture HIV-antigen plasmid DNA), CTIC +5.4% (CTI BioPharma and Baxter (BAX) announce Phase 3 data of Pacritinib in patients with Myelofibrosis to be presented in late-breaking session at ASCO), NAVB +5.3% (reports data demonstrating that the Manocept molecule selectively binds to, and is continuously internalized by, tumor-associated macrophages and Kaposi's sarcoma tumor cells in a preclinical model), VLTC +4.7% (following 50%+ move higher yesterday), THLD +4.7% (announces preclinical data on TH-4000 suggesting that TH-4000 may overcome resistance to therapy with conventional EGFR-TKIs ), SALT +3.8% (announces agreements to sell seven newbuildings for $290 mln and the financing of an Ultramax Newbuilding for $17 mln), CAPR +3.1% (announces FDA Orphan Drug Designation for Allogeneic Cardiosphere-Derived Cells for the treatment of Duchenne Muscular Dystrophy), GDOT +2.9% (announces the award of a new mobile patent, directed to secure and private location sharing for location-aware mobile communication devices ), BTX +2.8% (Beckman Research Institute of City of Hope to manufacture clinical grade stem cells), BHP +2.7% (reports 9-month operational results; emains on track to deliver Group production growth of 16%), RIO +2.4% (in symp with BHP), VALE +1.9% (reports Q1 production), CRIS +1.8% (presents preclinical data on CUDC-427 at AACR), INTU +1% (reported TurboTax Online units grew 13% from prior year; expects FY15 consumer tax rev growth of ~8%, above prior guidance of +5-7%)<br/><br/><b>Analyst comments:</b> PTX +4.1% (initiated with a Overweight at Piper Jaffray), ALU +2.7% (upgraded to Outperform from Market Perform at Bernstein), ZGNX +2.4% (initiated with a Overweight at Piper Jaffray), NOK +2% (upgraded to Outperform from Market Perform at Bernstein), PKG +1.4% (upgraded to Buy from Hold at Deutsche Bank), YELP +1.2% (target raised to $58 at Brean Capital), BDSI +1.2% (assumed with a Overweight at Piper Jaffray), SCSS +1.2% (assumes/upgrades to Outperform from Neutral at Wedbush), MAS +0.9% (upgraded to Outperform from Mkt Perform at FBR Capital), GXP +0.9% (initiated with a Buy at Guggenheim)<br/><br/><b>Gapping down<br/>In reaction to disappointing earnings/guidance: </b>CREE -5.2%, CMG -4.8%, IRBT -4.7%, URI -4%, ISRG -3.4%, SMCI -2.3%, DFS -2.3%, TMO -1.8%, PFPT -1.5%<br/><br/><br/><b>Other news: </b>LOOK -11.1% (following 250%+ move higher yesterday), NRP -7.5% (announces plan to strengthen balance sheet, reduce debt and enhance liquidity; Reduce quarterly distribution), NVGN -4.9% (confirms Cantrixil receives orphan drug designation from FDA), GSK -1.4% (still checking), OREX -1% (received notification of a Paragraph IV certification for certain patents for Contrave which are listed in the FDA's Orange Book), VRA -0.5% (disclosed that Karen Peters, EVP of Retail and Wholesale has accepted another position and will be leaving the Company effective April 24, 2015)<br/><br/><b>Analyst comments:</b> RF -1.5% (downgraded to Sector Perform from Outperform at RBC Capital Mkts ), AGU -1.3% (downgraded to Sell from Neutral at Citigroup), WIBC -1.1% (downgraded to Outperform from Strong Buy at Raymond James)<br/><br/>Allikas: Briefing.com